Screener
Emergent Biosolutions EBS Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.
The source filing: Emergent Biosolutions’s 10-K, filed February 27, 2026.
- Filed
- Feb 26, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0001367644-26-000015
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Proceeds from sale of business | — | 110.2 | 270.2 |
| Net cash provided by investing activities | 69.4 | 125.2 | 212.3 |
| Financing Activities | |||
| Proceeds from the issuance of debt, net of lender fees | — | 219.0 | — |
| Proceeds allocated to warrants issued in conjunction with debt | — | 13.4 | — |
| Proceeds allocated to common stock issued in conjunction with debt | — | 9.3 | — |
| Principal payments on term loan facility | (100.0) | (198.2) | (164.6) |
| Proceeds from revolving credit facility | — | 65.0 | 20.0 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Emergent Biosolutions's debt issuance proceeds?
- Emergent Biosolutions (EBS) reported debt issuance proceeds of $0 in Q4 2025.
- How has Emergent Biosolutions's debt issuance proceeds changed year-over-year?
- Emergent Biosolutions's debt issuance proceeds decreased by 100.0% year-over-year, from $54.75M to $0.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Emergent Biosolutions's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude